Repair of the bicuspid aortic valve: A viable alternative to replacement with a bioprosthesis

Elena Ashikhmina, MD, PhD,a Thoralf M. Sundt III, MD,a Joseph A. Dearani, MD,a Heidi M. Connolly, MD,b Zhuo Li, MS,c and Hartzell V. Schaff, MDa

Objective: We sought to compare the safety and durability of bicuspid aortic valve repair versus replacement with a bioprosthesis.

Methods: We reviewed medical records of patients aged 18 years or older undergoing bicuspid aortic valve repair for aortic regurgitation from 1984 through 2007. We analyzed early outcomes and predictors of aortic valve replacement after initial repair. Patients with repair were compared with an age- and sex-matched cohort who had replacement with a bioprosthesis. Overall survival and survival free from reoperations were compared between groups.

Results: The mean follow-up period for 108 consecutive patients with repair was 5.1 (standard deviation, 4.1) years. The initially repaired valve was subsequently replaced in 19 (18%) patients. No bicuspid aortic valve repair technique or morphologic characteristic included in univariate risk factor analysis was associated with increased probability of replacement after initial repair. The 5- and 10-year survival rates after repair were 96% and 87%, respectively. Freedom from valve replacement was 96%, 89%, and 49% at 1, 5, and 10 years after repair, respectively. A separate analysis of 81 matched patients with repair or receipt of an aortic valve bioprosthesis showed no significant difference in 10-year survival (72% vs 79%, P = .13) or freedom from reoperation between groups (90% vs 98% and 72% vs 64% in 5 and 10 years, respectively; P < .12).

Conclusions: Bicuspid aortic valve repair is a viable alternative to replacement with a bioprosthesis because durability and safety are similar between both surgical management methods for aortic regurgitation. After initial repair, approximately half of the patients require aortic valve replacement within 10 years. (J Thorac Cardiovasc Surg 2010;139:1395-401)
Abbreviations and Acronyms

AR = aortic regurgitation
AV = aortic valve
AVR = aortic valve replacement
BAV = bicuspid aortic valve
SD = standard deviation

had a dilatation of greater than 45 mm, it was replaced with a supracoronary tube graft.

Operations were performed with nonthoracic cardiopulmonary bypass, and hypothermic antegrade blood cardioplegia was used for myocardial protection. The standard technique for surgical treatment of AR in a patient with BAV has undergone evolution over time. Before 2000, most valves were repaired with triangular resection and suture repair of the median raphe.6 After 2000 and in patients with pliable cusps, prolapse was most likely corrected with plication of the median raphe without resection. Intraoperative transesophageal echocardiographic analysis was used for all study patients.

Univariate analysis was performed to identify risk factors significant for BAV replacement after initial repair. The durability of BAV repair was evaluated by estimating the freedom from aortic valve replacement (AVR). Safety of the procedure was judged with the incidence of early postoperative complications and survival. To evaluate the influence of change in operative techniques depending on the era of operation, we divided study patients into 2 subgroups (ie, those who underwent operations before 2000 and those who underwent operations in 2000 or later) and compared results of analysis of freedom from AVR between the 2 subgroups. Furthermore, we performed the same analysis, excluding patients who had AVR but whose primary indication for reoperation was not BAV repair failure.

To assess the feasibility of BAV repair compared with other conventional techniques of AR management, we matched our study cohort with patients who underwent AVR with a bioprosthesis; patients were matched by year of operation (±5 years), age, and sex. Survival and freedom from reoperation were compared between the 2 groups.

Descriptive statistics for categorical variables are reported as frequencies and percentages; continuous variables are reported as means (standard deviations [SDs]) or medians (ranges), as appropriate. Categorical variables were compared with the \( \chi^2 \) test. Continuous variables were compared with the 2-sample \( t \) test or Wilcoxon rank sum test, as appropriate. The Kaplan–Meier method was used to draw survival curves and calculate 5- and 10-year survival statistics and freedom from AVR. Cox proportional hazards regression models were used to find the univariate predictors of time of AVR.

RESULTS

The study group contained 108 consecutive patients who met the inclusion criteria and had given consent to participate in research. Baseline characteristics of patients undergoing BAV repair are listed in Table 1. The mean age was 41 years, and most patients were men. No patient had acute endocarditis; 9 (8%) patients had healed lesions and a history of treated endocarditis. The primary indication for the operation was moderately severe or severe AR in 90 (83%) patients, and severe mitral regurgitation was associated with at least moderate AR in 9 (8%) patients. Another 9 patients were sent to the surgical department because of an ascending aortic aneurysm and had concomitant repair of significant AR.

Operative Techniques

Isolated BAV repair was performed in 61 (56%) patients. AV repair was combined with graft replacement in 15 patients and with reduction aortoplasty in 8 patients for dilatation of the ascending aorta (minimum, 49 mm); 11 patients had concomitant mitral valve repair. Other concomitant procedures are listed in Table 1.

Surgical inspection identified a number of mechanisms of BAV regurgitation. The most common finding was scarring and retraction of the rudimentary raphe of a conjoint cusp. Other mechanisms included prolapse of both aortic cusps or of a conjoint cusp. In general, the cusps were thin and pliable, and in 83 (77%) patients the cusps had no calcification.

The most common technique for BAV repair was commissural plication combined with triangular resection of the retracted rudimentary raphe. Overall, 101 patients had commissural plication. However, the operative methods changed over time. From 1984 through 1999, the retracted median raphe was excised in 24 patients and plicated in 1 patient; from 2000 through 2007, the raphe was excised in 39 patients and plicated in 19 patients.

After initial termination, cardiopulmonary bypass was resumed in 8 (7%) patients: for residual AR noted with intraoperative transesophageal echocardiographic analysis in 5 patients; for mitral valve repair, tricuspid valve repair, or both in 2 patients; and for closure of an iatrogenic ventricular septal defect acquired during decalcification of the interventricular septum in 1 patient. In 2 patients a brief period of circulatory arrest (12 and 15 minutes, respectively) was used to facilitate distal anastomoses of graft repair of ascending aortic aneurysms.

Intraoperative transesophageal echocardiographic analysis was performed in 105 (97%) patients; 3 patients without transesophageal echocardiographic analysis underwent operations in 1984 (2 patients) and 1986 (1 patient). None of the patients left the operating room with greater than mild residual AR, and the mean transvalvular gradient was 16 mm Hg (SD, 9 mm Hg).

Echocardiographic Characteristics

All patients with BAV underwent preoperative transthoracic echocardiographic analysis. The mean grade of AR in study patients was 3.2 (SD, 1.0) on a scale of 1 to 4. For most patients, left ventricular systolic function was normal; the mean of the left ventricular ejection fraction was 59% (SD, 6%). Aortopathy was common, and the mean diameter of the proximal ascending aorta was 41 mm (SD, 5 mm) in the study compared with 26 mm (SD, 3 mm) reported as a reference range by Triulzi and colleagues.7

Results of postoperative follow-up echocardiographic analyses at least 1 year after BAV repair were available in 46 (43%) patients who were free from AVR (Table 2). Statistically significant decreases in the left ventricular
systolic and diastolic dimensions and the left ventricular mass were observed at a mean of 4.6 years (SD, 3.5 years) after BAV repair. A decrease in AV orifice and augmentation of gradient across the AV were consequences of AV repair technique.

### Outcomes, Safety, and Durability of BAV Repair

Among the 108 patients undergoing BAV repair, the mean follow-up period was 5.1 years (SD, 4.1 years; median, 4.1 years; range, 5 days to 22.9 years). In 2 patients no follow-up information was available beyond the initial hospitalization. Follow-up beyond the first postoperative year was available for 95 (88%) patients, and 15 (14%) patients had follow-up beyond 10 years postoperatively.

No early deaths occurred, and 7 (6%) patients died late. Cause of death was unknown in 4 patients, death was cardiac related in 2 patients, and 1 patient died suddenly. The 1-, 5-, and 10-year survival rates were 99%, 96%, and 87%, respectively, which are similar to those of an age- and sex-matched general population (Figure 1, A).

Overall, 19 patients had subsequent AVR, and cumulative risk of reoperation for AVR is shown in Figure 1, B. Two AVRs were performed during initial hospitalization because of severe AR identified 4 and 6 days, respectively, after initial BAV repair. One patient underwent BAV reoperation during the same hospitalization; his valve was subsequently replaced 2 years postoperatively. Failure of the repair was the primary indication for reoperation in 14 of the 19 patients. The repair failure led to severe AR in 9 patients, aortic stenosis in 2 patients, and mixed aortic stenosis and AR in 1

### TABLE 2. Echocardiographic changes for patients with echocardiographic follow-up of 1 year or more after BAV repair

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients (n = 46)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before BAV repair, mean (SD)</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>59 (6)</td>
</tr>
<tr>
<td>LV end-diastolic dimension, mm</td>
<td>61 (8)</td>
</tr>
<tr>
<td>LV end-systolic dimension, mm</td>
<td>41 (6)</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>286 (70)</td>
</tr>
<tr>
<td>LA volume index, mL/m²</td>
<td>31 (14)</td>
</tr>
<tr>
<td>Aortic dimensions, mm</td>
<td></td>
</tr>
<tr>
<td>Anulus</td>
<td>29 (4)</td>
</tr>
<tr>
<td>Valsalva sinuses</td>
<td>42 (6)</td>
</tr>
<tr>
<td>Sinotubular junction</td>
<td>35 (5)</td>
</tr>
<tr>
<td>Proximal ascending aorta</td>
<td>42 (6)</td>
</tr>
<tr>
<td>Mid–ascending aorta</td>
<td>41 (8)</td>
</tr>
<tr>
<td>Aortic arch</td>
<td>31 (6)</td>
</tr>
<tr>
<td>Mean AV pressure gradient, mm Hg</td>
<td>10 (4)</td>
</tr>
<tr>
<td>AV orifice (TVI), cm²</td>
<td>3.8 (1.5)</td>
</tr>
<tr>
<td>Regurgitation grade (scale, 1–4)</td>
<td></td>
</tr>
<tr>
<td>Aortic valve</td>
<td>3.1 (1.0)</td>
</tr>
<tr>
<td>Mitral valve</td>
<td>1.0 (0.8)</td>
</tr>
<tr>
<td>Tricuspid valve</td>
<td>0.8 (0.4)</td>
</tr>
<tr>
<td>Pulmonary valve</td>
<td>0.6 (0.5)</td>
</tr>
<tr>
<td>RV systolic pressure, mm Hg</td>
<td>34 (12)</td>
</tr>
</tbody>
</table>

VA, Bicuspid aortic valve; SD, standard deviation; LVEF, left ventricular ejection fraction; LV, left ventricular; LA, left atrium; AV, aortic valve; TVI, time velocity integral; RV, right ventricular. *Patients free from AVR; mean echocardiographic follow-up was 4.6 years (SD, 3.5 years; maximum, 12.7 years).
patient; in 2 patients the indication for late AVR was unknown. For 5 patients, late AVR was performed during a reoperation for aortic aneurysm \((n = 1)\), aortic dissection \((n = 1)\), severe angina \((n = 1)\), severe mitral regurgitation \((n = 1)\), and persistent hemolysis \((n = 1)\), likely because of red cell trauma from an annuloplasty ring used during prior concomitant mitral valve repair.

At reoperation for AVR, 17 patients received mechanical prostheses, and 2 patients received bioprostheses. AVR was combined with mitral valve replacement in 2 patients and with coronary artery bypass grafting in 1 patient.

To evaluate the possible effect of a surgeon’s learning curve for the procedure, we stratified patients according to the era of operation. We found that there was a tendency toward a lower risk of reoperation for AVR in patients who underwent repair in 2000 or later \((P = .06; \text{Figure 1, C})\). To eliminate the confounding effect of late AVR during surgical intervention for another cardiac problem, we performed a similar analysis that included only the 14 patients who had late AVR caused by failure of the initial repair. The analysis showed that the tendency toward improved outcome in recent years persisted \((P = .13; \text{Figure 1, D})\).

**Outcomes, Safety, and Durability of BAV Repair Versus AVR With a Bioprosthesis**

To place the outcomes of BAV repair in perspective, we matched these patients for age, sex, and year of operation to control patients who had AVR with bioprostheses. We were able to identify 81 matched pairs from our database. Most (68%) of the group had AVR with Carpentier–Edwards pericardial bioprostheses. The mean age was 44 years (SD, 13 years) for patients with BAV repair and 45 years (SD, 13 years) for patients with AV bioprostheses \((P = .33)\). Durations of cardiopulmonary bypass and cross-clamping were longer in patients with AVR than in those with BAV repair (89 minutes [SD, 44 minutes] vs 53 minutes [SD, 27 minutes] and 66 minutes [SD, 34 minutes] vs 39 minutes [SD, 18 minutes], respectively; \(P < .001\)).

The length of available follow-up was similar among patients with BAV repairs and patients with AVR (4.2 years [SD, 3.2 years] vs 4.2 years [SD, 3.5 years]). Overall survival was similar for patients undergoing valve repair and those undergoing valve replacement (Figure 2, A). Risk of reoperation was also similar between the 2 groups \((P = .12; \text{Figure 2, B})\). Among matched patients with BAV repairs, 4 underwent reoperation because of causes unrelated to failure of BAV repair. After excluding these patients (and their matching cohort with bioprostheses), we again compared the risk of reoperation between the 2 groups \((n = 77)\) and found no statistical difference in freedom from reoperation \((P = .66; \text{Figure 2, C})\).

Early postoperative complications were more frequent among patients with AVR. Overall, 37 (46%) patients with aortic bioprostheses had complicated postoperative recovery; in the BAV repair group 24 (30%) patients had some complication after surgical intervention \((P = .04)\).
The major difference between the 2 groups was the requirement of prolonged mechanical ventilation in 6 (77%) patients with AVR; no patient with BAV repair received mechanical ventilation for more than 24 hours (P = .03). No statistically significant difference was found in the incidence of any other early postoperative complications, such as sternal wound infection (P = .99), renal failure (P = .99), onset of atrial fibrillation (P = .13), pneumonia (P = .12), sepsis (P = .50), or re-exploration for bleeding (P = .99). During late follow-up, endocarditis was reported in 4 patients who had AVR, and stroke occurred in 3 patients; no episode of endocarditis or stroke occurred in patients who had BAV repair.

**Risk Factors of BAV Repair Failure**

Several candidate variables were entered into the univariate analysis to discriminate potential risk factors related to time of AVR: age at original BAV repair; sex; body mass index; year of operation; era of operation (before 2000 or after 2000); left ventricular function; concomitant cardiac pathologic factors (eg, coarctation); AV morphologic characteristics as described by the operating surgeon, including calcification; AV repair techniques; concomitant procedures; and the mean AV gradient at recent follow-up trans-thoracic echocardiographic analysis. None of these variables were statistically significant in predicting the risk of AVR after BAV repair as it related to time of replacement.

**DISCUSSION**

AV repair has several potential advantages over AVR for younger patients with AR caused by BAV. Although valve repair often includes commissural plication sutures, which can narrow the annulus, preservation of the dynamics of the native valve annulus and tissue might have hemodynamic benefits over a rigid prosthetic valve stent. Also, risks of thromboembolic events, anticoagulation-related complications, and endocarditis appear to be reduced after valve repair compared with after replacement. However, as outlined in the 2006 American College of Cardiology/American Heart Association Guidelines for the Management of Patients With Valvular Heart Disease, AV repair involves a “lack of uniform applicability [and] lack of widespread experience with surgical techniques.” Furthermore, there are no clear indications on when repair should be attempted, and data showing its safety and durability are limited. Most publications in the medical literature report either a relatively short follow-up period (2–4 years) or a small number of patients with a longer follow-up period.

Also, assessment of results of AV repair is confounded because most reports describe mixed groups of patients, including those with tricuspid and bicuspid valve repairs, as well as valve repair performed during procedures for aortic root reconstruction. In a study of 54 patients, Rao and associates reported survival rates of 98% and 74%, respectively, at 5 and 10 years after repair of AR for patients

---

**FIGURE 2.** Survival and risk of reoperation in matched groups after bicuspid aortic valve (BAV) repair and aortic valve replacement (AVR) with a bioprosthesis. A, Survival of patients after BAV repair matched to patients who underwent AVR with a bioprosthesis. B, Risk of reoperation in matched patients who underwent BAV repair or AVR with a bioprosthesis. C, Risk of reoperation in matched patients who underwent BAV repair or AVR with a bioprosthesis after exclusion of patients and their matched pairs who underwent reoperation for indications not related to BAV repair failure.
with congenital heart disease. Of these patients, 43% had BAV. de Kerchove and coworkers reported a 99% 4-year survival rate for patients with AV repair, of whom 53% had BAV. In an earlier study from our institution in a mixed group of patients undergoing AV repairs, of whom 34% had BAV, freedom from cardiac death was 96% at 5 years.

In contrast to these earlier reports, the present investigation focused on outcomes of a homogenous group of patients with BAV regurgitation. After valve repair, patient survival rates at 1, 5, and 10 years postoperatively were 99%, 96%, and 87%, respectively, which are similar to those of the general US population. We also observed no significant difference in the survival of patients undergoing AV repair compared with that seen in matched patients undergoing AVR with a bioprosthesis, compared with those of the general US population. We observed no significant difference in the survival of patients undergoing AV repair compared with that seen in matched patients undergoing AVR with a bioprosthesis, compared with those of the general US population. We agreed with the systematic approach suggested by Pettersson and colleagues based on the echocardiographic evaluation. In their study, a joint cusp tissue restriction and deficiency, combined with cusp thickening and cusp calcification, were unfavorable features for repairability. We believe that these characteristics also influence late durability when such valves are repaired. Important, too, are the criteria for successful repair, which include a grade of AR of 1 or less and a mean AV gradient of less than 15 mm Hg or a peak AV gradient of less than 30 mm Hg.

Nevertheless, the cause of deterioration of BAV repair continues to be unclear. Several studies have investigated risk factors for failure of BAV repair. Casselman and coworkers described left ventricular dysfunction as a predictor of immediate, persistent AR of more than +1 after BAV repair, but they did not identify risk factors for late deterioration. Nash and colleagues reported echocardiographic parameters associated with increased likelihood of successful BAV repair, and these parameters included an eccentric jet of AR, absence of cuspal or commissural thickening, and lack of cusp calcification. Multivariate analysis by de Kerchove and coworkers suggested that methods of repair of the prolapsed cusp and increased left ventricular end-diastolic diameter were predictors of BAV repair failure. In our study none of the variables that potentially could increase the risk of AVR after BAV repair turned out to be statistically significant. It is possible that some other factors that were not tested but were associated with repair failure or with the numbers of patients and events (replacements), as well as the duration of follow-up, were not sufficient to identify risk factors.

Debates are ongoing over the most reliable technique of AV repair. The change of surgical technique from triangular resection to tissue-sparing plication of the midportion of the joint cusp is expected to improve repair durability. However, in the series reported by Aicher and associates, triangular resection of a portion of the prolapsing cusp did not compromise midterm durability of repair. Our current preference for plication rather than cusp resection evolved with increasing experience. We initially followed the

<table>
<thead>
<tr>
<th>Study report</th>
<th>Follow-up, mean (SD), y</th>
<th>Years of study</th>
<th>No. of patients</th>
<th>Age, mean (SD), y</th>
<th>1 y</th>
<th>5 y</th>
<th>7–8 y</th>
<th>10 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alsoufi and coworkers</td>
<td>3.5 (2.7)</td>
<td>1993–2005</td>
<td>71</td>
<td>42 (13)</td>
<td>97</td>
<td>90</td>
<td>82</td>
<td>NA</td>
</tr>
<tr>
<td>Casselman and coworkers</td>
<td>5.1 (2.4)</td>
<td>1988–1997</td>
<td>94</td>
<td>38 (10)</td>
<td>95</td>
<td>87</td>
<td>84</td>
<td>NA</td>
</tr>
<tr>
<td>Davierwala and coworkers</td>
<td>2.6 (2.1)</td>
<td>1993–2002</td>
<td>44</td>
<td>39 (12)</td>
<td>95</td>
<td>91</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Fraser and coworkers</td>
<td>2.0 (1.3)</td>
<td>1988–1993</td>
<td>72</td>
<td>39 (11)</td>
<td>94</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kin and coworkers</td>
<td>3.3 (1.9)</td>
<td>1993–2000</td>
<td>19</td>
<td>42 (17)</td>
<td>87</td>
<td>76</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Present study</td>
<td>5.1 (4.1)</td>
<td>1984–2007</td>
<td>108</td>
<td>41 (13)</td>
<td>96</td>
<td>89</td>
<td>75</td>
<td>49</td>
</tr>
</tbody>
</table>

SD, Standard deviation; NA, not applicable. *According to mean years of follow-up after bicuspid aortic valve repair.
methods described by Cosgrove and colleagues, which involved excision of the raphe of the prolapsing cusp, and this method is still useful when there is marked thickening of this area. However, when the conjoint cusp is very pliable and thickness is near normal, plication to shorten the free edge is done easily and avoids risk of sutures pulling through the thinner areas of the midcusp. Although not statistically significant, the rate of reoperation after BAV repair for patients who underwent operations after 2000 was lower than for patients undergoing operations in the previous decade. This lower rate likely reflects improved patient selection, as well as use of the plication method.

An important finding in the present study was the comparability of risk of reoperation for patients undergoing BAV repair versus AVR with a bioprosthesis. As shown in Figure 2, B and C, the cumulative risk of reoperation for patients with a bioprosthesis appears to increase sharply after 8 years, although our follow-up beyond this time is limited. Goland and associates reported that the risk of reoperation 10 years after AVR with a bioprosthesis reached 30% to 50% depending on the decade when the initial operation was performed. In addition to the relatively high rate of re-intervention, patients undergoing AVR with a bioprosthesis are still at risk for prosthetic valve–related complications, particularly prosthetic valve endocarditis and thromboembolism, and the risks of these complications were notably low (ie, no events) among patients undergoing valve repair.

**Study Limitations**

The mean age of the study patients was 41 years (SD, 13 years), and our reported results do not assess the safety and durability of BAV repair in a younger population. All patients in the study had preserved left ventricular ejection fraction (≥45%), and thus no conclusion can be made about the feasibility of BAV repair in patients with impaired myocardial performance. Also, the follow-up period is relatively short; with additional time, repaired valves might have calcification and stenosis. As previously reported, we matched control patients with bioprostheses for only 81 of the 108 patients in the overall study. Nevertheless, our data provide a longer follow-up period on repaired BAV than prior reports. Finally, the end point of our statistical analysis was reoperation but not the grade of AR, and thus the incidence of severe AR (eg, repair failure) might be underestimated.

**CONCLUSION**

BAV repair is a safe and durable technique for AR management. It is a viable alternative to AVR with a bioprosthesis because a comparison of these 2 therapeutic approaches shows no advantage in survival and durability.

---

**References**